KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pfizer (PFE) Other Non Operating Income (2016 - 2025)

Pfizer (PFE) has disclosed Other Non Operating Income for 17 consecutive years, with -$4.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Other Non Operating Income fell 91.43% to -$4.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$6.7 billion, a 53.24% decrease, with the full-year FY2025 number at -$6.7 billion, down 53.24% from a year prior.
  • Other Non Operating Income was -$4.5 billion for Q4 2025 at Pfizer, down from -$518.0 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $1.7 billion in Q4 2021 to a low of -$4.5 billion in Q4 2025.
  • A 5-year average of -$511.3 million and a median of -$434.0 million in 2022 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 628.42% in 2021, then tumbled 1583.02% in 2024.
  • Pfizer's Other Non Operating Income stood at $1.7 billion in 2021, then crashed by 162.68% to -$1.1 billion in 2022, then surged by 114.96% to $159.0 million in 2023, then plummeted by 1583.02% to -$2.4 billion in 2024, then crashed by 91.43% to -$4.5 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Other Non Operating Income are -$4.5 billion (Q4 2025), -$518.0 million (Q3 2025), and -$739.0 million (Q2 2025).